94
Participants
Start Date
May 17, 2024
Primary Completion Date
May 1, 2027
Study Completion Date
May 1, 2029
Encorafenib
Encorafenib is administered orally at a daily dose of 300 mg, typically in the form of four 75 mg capsules taken together.
Cetuximab
Cetuximab is administered intravenously every two weeks at a dose of 500 mg/m².
Bevacizumab
Bevacizumab is administered intravenously every two weeks at a dose of 5 mg/kg.
RECRUITING
Vall d'Hebron Hospital, Barcelona
Vall d'Hebron Institute of Oncology
OTHER